Beth israel medical center
Brigham and womens hospital
Dana farber cancer institute
Hackensack university medical center
Jacobi medical center
Lenox hill hospital
Montefiore medical center
New york and presbyterian hospital
New york methodist hospital
North shore university hospital
Memorial Hospital For Cancer and Allied Diseases
New York Presbyterian Hospital/New York Weill Cornell Center
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.
Blood., Feb;119(7):1665-70 (2012)
Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma.
J. Exp. Med., Aug;208(9):1799-807 (2011)
Expert second-opinion pathology review of lymphoma in the era of the World Health Organization classification.
Ann. Oncol., Jan;23(1):159-66 (2012)
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.
Clin. Cancer Res., Apr;17(8):2493-501 (2011)
Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
Blood., Dec;116(23):4934-7 (2010)
Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantation.
Biol. Blood Marrow Transplant., Dec;15(12):1538-42 (2009)
High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging.
Br. J. Haematol., Mar;148(6):890-7 (2010)
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.
J. Clin. Oncol., Apr;28(11):1896-903 (2010)
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phas
Br. J. Haematol., Apr;145(1):34-9 (2009)
Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma.
Br. J. Haematol., Jul;146(2):158-63 (2009)
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.
Br. J. Haematol., Sep;146(6):652-5 (2009)
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.
J. Clin. Oncol., Sep;27(26):4357-64 (2009)
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.
J. Clin. Oncol., Feb;27(4):491-7 (2009)
Overview of lymphoma diagnosis and management.
Radiol. Clin. North Am., Mar;46(2):175-98, vii (2008)
Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.
Clin Adv Hematol Oncol., Jun;6(6):437-45 (2008)
Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma.
Cancer., Dec;110(11):2528-34 (2007)
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.
Br. J. Haematol., Nov;139(3):425-8 (2007)
Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma.
Br. J. Haematol., Jul;134(2):202-7 (2006)
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.
J. Clin. Oncol., Apr;24(10):1575-81 (2006)
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
J. Clin. Oncol., Jan;24(1):166-73 (2006)